Results 201 to 210 of about 102,476 (312)

Clock Modulation by Naringenin Suppresses Lipogenesis and Promotes Adipose Tissue Browning. [PDF]

open access: yesJ Cell Physiol
Xiong X   +6 more
europepmc   +1 more source

Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases

open access: yesObesity Reviews, EarlyView.
ABSTRACT Epidemiological evidence shows that obesity increases the risk of developing metabolic diseases. Nevertheless, the mechanisms behind this connection remain underappreciated. The substantial impact of these disorders on global health has led to extensive research efforts aimed at identifying the pathophysiological links between them.
Ghadeer Alhamar   +4 more
wiley   +1 more source

Targeting lipogenesis promotes the synergistic effect of the selective HDAC6 inhibitor ITF3756 with bortezomib in colon cancer cells. [PDF]

open access: yesFront Pharmacol
Franzò M   +7 more
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

open access: yesObesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira   +8 more
wiley   +1 more source

Beyond Deterministic Fetal Programming: Intrauterine Exposures and the Multifactorial Origins of Adiposity

open access: yesObesity Reviews, EarlyView.
ABSTRACT Excess adiposity is not a recently developed problem but has existed since at least the upper Paleolithic, allowing evolutionary selection pressures to adapt the physiology of the pregnant woman and the feto‐placental unit for maternal and fetal protection.
Gernot Desoye   +6 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

open access: yesObesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani   +8 more
wiley   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

open access: yesObesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy